Supreme Court Strips Consumers of Right to Sue Pesticide Companies for Failure to Warn of Cancer Risks

Last week, in a landmark decision reverberating through legal and public health circles, the Supreme Court of the United States, in the case of Monsanto v. Durnell, effectively dismantled a long-standing legal pathway for individuals to seek redress in state courts against pesticide manufacturers. This ruling eliminates the right of consumers to hold companies accountable for failing to warn them about potential cancer risks or other diseases associated with their products, provided the Environmental Protection Agency (EPA) has not mandated such warnings. The 7-2 majority decision has been met with both celebration from the industry and fierce condemnation from consumer advocates, setting a new precedent that significantly redefines corporate liability in the chemical sector.

The Supreme Court’s Landmark Decision and the Doctrine of Preemption

The core of the Supreme Court’s ruling centered on the legal doctrine of "preemption." In its 7-2 decision, the Court sided with Monsanto, now a subsidiary of Bayer, by asserting that individuals who contract cancer from using a pesticide are "preempted," or legally prohibited, from suing manufacturers for failing to warn them of cancer risks. This preclusion applies if the EPA, the federal agency responsible for regulating pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), has not explicitly required a cancer warning during the pesticide’s approval process. The majority opinion effectively interprets FIFRA as preempting state-level failure-to-warn claims when the EPA has approved a product label without such warnings, arguing that allowing state tort claims would undermine the uniformity of federal pesticide regulation.

The Durnell case is a bellwether for tens of thousands of similar lawsuits pending in lower courts across the nation. These cases predominantly involve plaintiffs who allege that Monsanto’s flagship herbicide, Roundup, and its active ingredient, glyphosate, caused their non-Hodgkin lymphoma. "Failure to warn" claims, which contend that manufacturers knew or should have known about potential dangers but failed to inform consumers, have been a foundational element of these state-law-based actions. The Supreme Court’s ruling is widely expected to create substantial hurdles for or outright block many pending lawsuits seeking compensation for cancers allegedly caused by Roundup or other pesticides, and it could severely limit the viability of comparable future cases.

Background to the Battle: Roundup, Glyphosate, and a Legacy of Litigation

Roundup, first introduced by Monsanto in 1974, quickly became one of the most widely used herbicides globally. Its active ingredient, glyphosate, gained immense popularity, especially with the introduction of "Roundup Ready" genetically modified crops designed to withstand the chemical, allowing farmers to spray fields without harming their crops. For decades, Monsanto maintained that glyphosate was safe and non-carcinogenic.

However, scientific scrutiny intensified over time. In 2015, the International Agency for Research on Cancer (IARC), a research arm of the World Health Organization (WHO), classified glyphosate as "probably carcinogenic to humans." This classification ignited a firestorm of controversy and triggered an unprecedented wave of litigation against Monsanto. Plaintiffs, primarily farmers, landscapers, and home gardeners who had extensively used Roundup, began filing lawsuits alleging that exposure to the herbicide led to their non-Hodgkin lymphoma.

The initial trials yielded significant victories for plaintiffs, with juries awarding substantial damages, including punitive damages, against Monsanto. These early verdicts, such as those in the cases of Dewayne Johnson, Edwin Hardeman, and Alva and Alberta Pilliod, established a precedent that glyphosate-based herbicides could cause cancer and that Monsanto had failed to adequately warn consumers of the risks. These judgments led to thousands more lawsuits being filed, culminating in the formation of a Multi-District Litigation (MDL) in the federal court system to manage the voluminous and complex litigation. Bayer’s acquisition of Monsanto for approximately $63 billion in 2018 meant that the German pharmaceutical and life sciences company inherited this sprawling legal challenge, which has since cost it billions.

The Heart of the Matter: "Failure to Warn" Claims and FIFRA

At the core of the preemption argument lies the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), enacted in 1947 and substantially amended over the years. FIFRA mandates that all pesticides sold or distributed in the U.S. must be registered with the EPA. As part of this registration process, the EPA reviews the pesticide’s ingredients, proposed labeling, and usage instructions to ensure it can be used without "unreasonable adverse effects on the environment." If the EPA approves a label, that label is legally binding.

The question before the Supreme Court was whether FIFRA’s provisions for federal approval of pesticide labels preempted state common-law claims, specifically "failure to warn" claims, which seek damages for injuries caused by inadequate labeling. Historically, courts have grappled with the interplay between federal regulatory schemes and state tort law. Advocates for preemption argue that allowing state-level lawsuits based on a failure to warn, when the EPA has already approved a label, would create a patchwork of inconsistent labeling requirements, disrupting interstate commerce and undermining the EPA’s authority. Conversely, opponents argue that federal approval of a label sets a minimum standard, and states should retain the right to impose higher standards through tort law, especially when federal agencies may be slow to act on emerging scientific evidence. The Supreme Court’s majority sided with the former interpretation, giving federal agency approval a much stronger preemptive effect than many public interest groups believed was intended by Congress.

Chronology of a Legal Saga

The journey from initial product launch to a Supreme Court ruling spans decades:

• 1974: Monsanto introduces Roundup, with glyphosate as its active ingredient.
• 1990s: Introduction of "Roundup Ready" crops significantly increases glyphosate use.
• 2015: The International Agency for Research on Cancer (IARC) classifies glyphosate as "probably carcinogenic to humans." This sparks the first wave of lawsuits.
• 2016: A federal Multi-District Litigation (MDL) is established in the U.S. District Court for the Northern District of California to consolidate federal Roundup lawsuits. Judge Vince Chhabria is appointed to oversee it.
• 2018:
  • Bayer acquires Monsanto for approximately $63 billion, inheriting the extensive litigation.
  • Dewayne Johnson, a former groundskeeper, wins the first Roundup cancer trial, with a California jury awarding $289 million (later reduced).
• 2019:
  • Edwin Hardeman wins the second federal bellwether trial, awarded $80 million (later reduced).
  • Alva and Alberta Pilliod win the third trial, awarded over $2 billion (later reduced to $87 million). These verdicts validate the "failure to warn" claims.
• 2020-2021: Bayer attempts to settle the bulk of the litigation, allocating over $11 billion for settlements. However, a proposed class action settlement aimed at resolving future claims faces judicial skepticism and is largely rejected in its initial form.
• 2022-2025: Appeals continue, with some state-level wins for plaintiffs and some reversals on appeal. Bayer continues to explore strategies to manage future liability, including seeking Supreme Court intervention on the preemption issue.
• Last Week (July 2026): The Supreme Court issues its 7-2 decision in Monsanto v. Durnell, ruling that federal law preempts state-level failure-to-warn claims for EPA-approved pesticide labels.

Reactions from the Front Lines: Advocates, Corporations, and the Judiciary

The ruling has elicited starkly contrasting responses. George Kimbrell, Legal Director at the Center for Food Safety (CFS), a prominent nonprofit advocating on food and agriculture issues, expressed profound disappointment. "Overturning decades of well-settled law, the Supreme Court eliminated one way the public held pesticide corporations accountable for their products’ harms," Kimbrell stated. He emphasized, however, that the fight is far from over, highlighting the increased importance of EPA oversight and the potential for action at state and local levels. Kimbrell called the decision a "clarion, galvanizing call to continued action," urging Americans to demand that their representatives prioritize public health over corporate profits.

Carey Gillam, Editor-in-Chief at The New Lede and author of investigative books on Monsanto, including The Monsanto Papers, provided an insightful perspective on the immediate implications. "That depends on who you ask," Gillam told Corporate Crime Reporter. She noted Bayer’s jubilation, as the company believes the ruling will effectively end outstanding lawsuits and deter future ones by making it significantly harder for plaintiffs to prevail without the potent "failure to warn" argument. This sentiment was echoed in the financial markets, where Bayer’s stock surged 17 percent on the day of the ruling, signaling investor confidence in the reduced legal exposure.

However, Gillam also pointed out that some plaintiffs’ attorneys remain defiant, asserting that they can still pursue claims based on other grounds, such as negligence or design defects, arguing that the product itself is "more dangerous than can reasonably be expected." Yet, Gillam, who has closely followed these trials, acknowledged the practical difficulties. She explained that "failure to warn" claims resonated strongly with juries because they were straightforward: "Here is the science, there is abundant scientific research out that shows a connection… Why didn’t the company put that on the product, like a tobacco warning label? That resonated with jurors." Without this clear narrative, shifting to technical arguments about design defects could make cases much harder for juries to grasp, increasing litigation costs and potentially reducing punitive damages, which were a significant incentive for law firms to take on these expensive cases. This shift, Gillam suggested, might lead some firms to "move on to something where they can make a lot more money."

The ruling was not unanimous. Justices Neil Gorsuch and Ketanji Brown Jackson issued dissenting opinions, arguing that the majority’s interpretation of FIFRA was inaccurate and represented an overreach into states’ traditional authority to protect their citizens. Their dissents underscore the deep divisions within the Court regarding the balance between federal regulatory authority and state common law.

The Complexities of Mass Tort Litigation: MDL vs. Class Action

The current landscape of Roundup litigation involves a dual track: individual cases managed under a Multi-District Litigation (MDL) and a proposed class action settlement. An MDL, as explained by Gillam, is a mechanism to consolidate numerous individual lawsuits from different federal districts into one court for pretrial proceedings like discovery and expert witness testimony. This streamlines the process, but cases ultimately return to their original courts for trial on an individual basis. The vast majority of the approximately 170,000 cases have been resolved, with Bayer having paid over $11 billion. While some plaintiffs achieved multi-million or even multi-billion dollar punitive damage awards (later reduced), Bayer also prevailed in several trials.

The proposed class action, however, is distinct. Unlike individual MDL cases, a class action lumps all current and future claimants into a single group, with a settlement typically structured into tiers of payouts. Bayer has offered an additional $7.25 billion to settle this class action, which aims to resolve all remaining and future claims. This proposed settlement has been highly controversial. Judge Vince Chhabria, who oversees the MDL, notably described an earlier version of the class action settlement as "filthy" due to concerns about its fairness to plaintiffs and the substantial fees allocated to the attorneys who negotiated it, often referred to as "collusive class actions" when they appear to favor the defendant and a select group of plaintiffs’ attorneys. The class action settlement, filed in Missouri, is currently awaiting final approval, with a crucial hearing scheduled for July 9. The Supreme Court’s ruling will undoubtedly influence plaintiffs’ decisions on whether to "opt-in" or "opt-out" of this settlement, as the prospect of winning large verdicts in individual trials has significantly diminished.

Navigating the Future: Legal Strategies and Legislative Pushback

With the "failure to warn" avenue largely closed, plaintiffs’ attorneys will need to recalibrate their strategies. While claims of negligent design or manufacturing defects remain theoretically possible, proving these can be far more complex and costly than demonstrating a simple failure to inform consumers about known or probable risks. This legal shift places immense pressure on the EPA to be more proactive and stringent in its pesticide labeling requirements. As George Kimbrell stated, "EPA’s regulation of pesticides just became all the more vital to protecting the public health and public interest. We will continue to hold EPA accountable when it does not." Public interest groups are expected to intensify their advocacy for stronger federal oversight and more rigorous safety assessments of chemical products.

Beyond the courts, legislative efforts are already underway to counter the Supreme Court’s decision. Senator Cory Booker (D-NJ) has expressed intentions to introduce legislation that would effectively overturn the ruling by amending FIFRA to explicitly state that federal approval does not preempt state failure-to-warn claims. Congresswoman Chellie Pingree (D-ME) has already introduced similar legislation. These efforts are gaining traction with consumer protection advocates and public health coalitions, including the "Make America Healthy Again" (MAHA) movement, which is mobilizing grassroots support and threatening to make corporate accountability a key issue in upcoming elections. However, passing such legislation faces an uphill battle against powerful agricultural and chemical industry lobbying groups in Washington, D.C.

Broader Implications for Corporate Accountability

The Monsanto v. Durnell decision carries significant broader implications extending beyond pesticide litigation. It sets a precedent that could embolden other industries to seek similar preemption protections for products regulated by federal agencies. If federal approval of a label or product is interpreted as a shield against state tort claims, it could significantly diminish corporate accountability across various sectors, from pharmaceuticals to consumer goods. This raises critical questions about the balance of power between federal regulators, state courts, and corporate responsibility to consumers. Critics argue that it shifts the burden of proof and protection from manufacturers to federal agencies, which may be susceptible to political pressure or under-resourced to conduct exhaustive independent safety assessments. For consumers, it means fewer avenues for legal recourse when harmed by products that received federal approval but lacked adequate warnings.

Looking Ahead: The Paraquat Precedent?

Carey Gillam highlighted the ongoing "paraquat litigation" as the next major mass tort to watch. Paraquat, another highly toxic weed killer, is the subject of a similar MDL, with plaintiffs alleging it causes Parkinson’s disease. While smaller and newer than the Roundup litigation, it appears to be following a similar trajectory. Gillam expressed concern about the judge in the paraquat MDL, Judge Nancy Rosenstengel, who she believes is "putting a finger on the scale" to pressure plaintiffs into accepting what lawyers describe as "pitiful" settlements with manufacturers like Syngenta. The judge’s reported efforts to compel plaintiffs with Parkinson’s to undergo intense scrutiny if they refuse settlement offers raise ethical questions about judicial impartiality and the right to a trial. This emerging litigation underscores the continued challenges consumers face in holding powerful chemical companies accountable and the evolving dynamics of mass torts in the wake of decisions like Monsanto v. Durnell. The Supreme Court’s ruling may represent a significant victory for industry, but the battle for consumer protection and corporate responsibility is far from over.